The U.S. Food and Drug Administration approved the drug Sunitinib (marketed as Sutent) to treat patients with kidney cancer who are at high risk for tumor recurrence. Dr. Allan Pantuck, head of the UCLA Institute of Urologic Oncology’s Clinical Research Program, served on the Global Advisory Steering Committee that oversaw the conduct and progress of a clinical study of sunitinib and helped to present these findings to the FDA’s Oncologic Drugs Advisory Committee.
MedPage Today featured a study led by Dr. Alexandra Drakaki, assistant professor of medicine in the division of hematology and oncology at the David Geffen School of Medicine at UCLA, about a vaccine against metastatic renal cell carcinoma that showed stability and safety in a phase 1 clinical trial. Drakaki is also a member of the UCLA Jonsson Comprehensive Cancer Center.
Be Part of a Clinical Study.
Active Clinical Trials >
View answers to frequently asked questions
Why Choose the UCLA Institute of Urologic Oncology? >